CPRX Stock Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
Catalyst Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.83|
|52 Week High||US$17.22|
|52 Week Low||US$5.05|
|1 Month Change||-5.24%|
|3 Month Change||81.73%|
|1 Year Change||146.26%|
|3 Year Change||164.54%|
|5 Year Change||363.18%|
|Change since IPO||110.33%|
Recent News & Updates
Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition
Catalyst Pharmaceuticals (NASDAQ:CPRX) has jumped 8.6% after hours following word that the stock will join the S&P SmallCap 600 index. Catalyst is set to replace ManTech International (MANT) in the list. The Carlyle Group is nearing the close of its acquisition of ManTech. The change is effective prior to the open of trading on Thursday, Sept. 15.
|CPRX||US Biotechs||US Market|
Return vs Industry: CPRX exceeded the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: CPRX exceeded the US Market which returned -21.5% over the past year.
|CPRX Average Weekly Movement||10.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CPRX's weekly volatility (10%) has been stable over the past year.
About the Company
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.
Catalyst Pharmaceuticals Fundamentals Summary
|CPRX fundamental statistics|
Is CPRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPRX income statement (TTM)|
|Cost of Revenue||US$43.13m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.53|
|Net Profit Margin||31.97%|
How did CPRX perform over the long term?See historical performance and comparison
Is CPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CPRX?
Other financial metrics that can be useful for relative valuation.
|What is CPRX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CPRX's PE Ratio compare to its peers?
|CPRX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
CDMO Avid Bioservices
EBS Emergent BioSolutions
IRWD Ironwood Pharmaceuticals
CPRX Catalyst Pharmaceuticals
Price-To-Earnings vs Peers: CPRX is good value based on its Price-To-Earnings Ratio (24.2x) compared to the peer average (24.7x).
Price to Earnings Ratio vs Industry
How does CPRX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: CPRX is expensive based on its Price-To-Earnings Ratio (24.2x) compared to the US Biotechs industry average (14.9x)
Price to Earnings Ratio vs Fair Ratio
What is CPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||24.2x|
|Fair PE Ratio||23.4x|
Price-To-Earnings vs Fair Ratio: CPRX is expensive based on its Price-To-Earnings Ratio (24.2x) compared to the estimated Fair Price-To-Earnings Ratio (23.4x).
Share Price vs Fair Value
What is the Fair Price of CPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CPRX ($12.83) is trading below our estimate of fair value ($45.95)
Significantly Below Fair Value: CPRX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Catalyst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPRX's forecast earnings growth (14.8% per year) is above the savings rate (1.9%).
Earnings vs Market: CPRX's earnings (14.8% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: CPRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: CPRX's revenue (12.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: CPRX's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CPRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Catalyst Pharmaceuticals performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPRX has high quality earnings.
Growing Profit Margin: CPRX's current net profit margins (32%) are lower than last year (58.8%).
Past Earnings Growth Analysis
Earnings Trend: CPRX has become profitable over the past 5 years, growing earnings by 56.5% per year.
Accelerating Growth: CPRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CPRX had negative earnings growth (-27%) over the past year, making it difficult to compare to the Biotechs industry average (29.2%).
Return on Equity
High ROE: CPRX's Return on Equity (22.6%) is considered high.
Discover strong past performing companies
How is Catalyst Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CPRX's short term assets ($242.6M) exceed its short term liabilities ($22.5M).
Long Term Liabilities: CPRX's short term assets ($242.6M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: CPRX is debt free.
Reducing Debt: CPRX has not had any debt for past 5 years.
Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Catalyst Pharmaceuticals Dividend Yield vs Market|
|Company (Catalyst Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Catalyst Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate CPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CPRX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pat McEnany (75 yo)
Mr. Patrick J. McEnany, also known as Pat, co-founded Catalyst Pharmaceuticals, Inc. (formerly known as Catalyst Pharmaceutical Partners Inc.) in January 2002 and has been its Chairman and President since...
CEO Compensation Analysis
|Pat McEnany's Compensation vs Catalyst Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$632k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$604k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$3m||US$548k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$3m||US$524k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$901k||US$485k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$608k||US$473k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$1m||US$453k|
Compensation vs Market: Pat's total compensation ($USD2.09M) is below average for companies of similar size in the US market ($USD5.59M).
Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.
Experienced Management: CPRX's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: CPRX's board of directors are seasoned and experienced ( 14.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CPRX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|23 Sep 22||SellUS$713,940||Alicia Grande||Individual||60,000||US$11.90|
|16 Sep 22||SellUS$1,214,640||Alicia Grande||Individual||90,000||US$13.50|
|14 Sep 22||SellUS$472,000||Philip Coelho||Individual||30,000||US$15.75|
|14 Sep 22||SellUS$15,832,731||Patrick McEnany||Individual||1,027,611||US$15.41|
|14 Sep 22||SellUS$306,800||Donald Denkhaus||Individual||20,000||US$15.34|
|14 Sep 22||SellUS$778,650||Alicia Grande||Individual||50,000||US$15.57|
|13 Sep 22||SellUS$1,824,367||Steven Miller||Individual||107,933||US$17.11|
|29 Aug 22||SellUS$969,328||Alicia Grande||Individual||68,095||US$14.40|
|19 Aug 22||SellUS$198,667||Jeffrey Del Carmen||Individual||14,140||US$14.05|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Catalyst Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Catalyst Pharmaceuticals, Inc.
- Ticker: CPRX
- Exchange: NasdaqCM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.319b
- Shares outstanding: 102.82m
- Website: https://www.catalystpharma.com
Number of Employees
- Catalyst Pharmaceuticals, Inc.
- 355 Alhambra Circle
- Suite 801
- Coral Gables
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CPRX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2006|
|CN2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2006|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.